Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix CytoScan HD data on neuroblastoma cell lines

ABSTRACT: Affymetrix CytoScan HD data on neuroblastoma cell lines

PROVIDER: PRJNA862167 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

CytoScan HD array for multiple myeloma samples

Project description:Affymetrix CytoScan HD array for newly diagnosed multiple myeloma patients.

2021-02-10 | GSE164554 | GEO

Affymetrix CytoScan HD data on neuroblastoma cell lines

Project description:Neuroblastomas are characterized by recurrent segmental and/or numerical chromosomal abberations such as MYCN-amplification or 11q-deletion. To further elucidate recurrent chromosomal alterations, 16 neuroblastoma cell lines were investigated.

2022-11-10 | GSE209728 | GEO

Affymetrix CytoScan HD array data for patient with Intellectual Disabilities

Project description:Standard cytogenetic GTG-banding analysis (550 bands) revealed an interstitial deletion on 15q21q22 chromosomal region. Refinement of the 15q21.2 deletion intervals was conducted using aCGH (Cytoscan HD, Affymetrix) on DNA samples from the patient. This assay revealed the presence of submicroscopic alterations on chromosomes 1, 9 and 15. The result was arr[hg19] 9p24.1(6,619,823-6,749,335)x3, 1q44(248,688,586-248,795,277)x1, 15q21.2q22.2(50,848,301-61,298,006)x1. Affymetrix CytoScan HD arrays were performed according to the manufacturer's directions on DNA extracted from peripheral blood samples.

2014-06-21 | E-GEOD-58694 | biostudies-arrayexpress

Affymetrix CytoScan HD for autism spectrum disorder in children

Project description:Affymetrix CytoScan HD for autism spectrum disorder in children

| PRJNA472953 | ENA

Affymetrix CytoScan HD array data of iPSCs and iPSC-derived-NSPCs

Project description:Cytoscan HD analysis on DNA samples from iPSCs, iPS-derived NSPCs

2016-09-14 | GSE77995 | GEO

Affymetrix CytoScan HD array data for patient with Intellectual Disabilities

2014-06-21 | GSE58694 | GEO

two amniotic fluid sample performed by affymetrix cytoscan HD

Project description:The uploaded results of two samples were SNParray results in our research of which fetal CNVs were detected by noninvasive prenatal test (NIPT) and confirmed by microarray results. Sample ZNY162 received prenatal diagnosis because at 17 gestational week the pregnant woman received NIPT showing 23Mb microdeletion in Chr18. Later ultrasound examination showed developmental anomalies of feet and the 13th ribs. The pregnant woman received amniocentesis and SNParray at the 21st gestational week, which confirmed the existence of the microdeletion in Chr18. DNA was extracted from 10ml amniotic fluid and tested by Affymetrix CytoScan HD array to detect CNVs in whole genome, showing arr 18q22.3q23(69,461,933-78,014,123) Ã1. Sample LMQ155 received prenatal diagnosis because of advanced maternal age and NIPT result of a 2.29Mb microduplication in Chr13 at 15 gestational week. Amniocentesis was performed at the 17th gestational week. Affymetrix CytoScan HD array were used to detect fetal CNVs in whole genome, which showed arr 13q21.2(60,399,612-61,730,194) Ã3 that was consistent with NIPT result.

2016-11-16 | E-MTAB-4738 | biostudies-arrayexpress

Affymetrix CytoScan HD and OncoScan array data for malignant melanoma samples

Project description:Affymetrix CytoScan HD and OncoScan array data for malignant melanoma samples

| PRJNA767857 | ENA

Affymetrix CytoScan HD for autism spectrum disorder in children

Project description:Autism spectrum disorder (ASD) is a complex heterogeneous developmental disease with a significant genetic background that is frequently caused by rare copy number variants (CNV). The aim of the study was to identify new candidate genes for ASD in the studied cohort of ASD-diagnosed patients. We used chromosomal microarray analysis (CMA) - a Cytoscan HD (Affymetrix, Santa Clara, CA, USA) to detect CNV in 87 ASD patients and their relatives and evaluated their clinical significance. Pathogenic and likely pathogenic mutations were identified by CMA in 8 and 9 ASD patients, respectively. CMA revealed 89 rare CNV: 8 pathogenic, 12 designated VOUS - likely pathogenic, 12 VOUS - uncertain, and 57 VOUS - likely benign or benign. CNV (pathogenic/VOUS-likely pathogenic/VOUS - uncertain) overlapping the same gene in more than one patient were observed in DOCK8 gene and PARK2 gene. This work presents new evidence about the possible roles of PARK2 and DOCK8 in the etiology of ASD, and suggests CTNNA2 as a candidate gene for ASD risk.

2018-05-25 | GSE114870 | GEO

CytoScan HD array for multiple myeloma samples

Project description:CytoScan HD array for multiple myeloma samples

| PRJNA691214 | ENA